Navigation Links
Come Visit Visikol at the College of American Pathologists at Booth #216

When a lot of researchers think of Visikol, they think of the companies tissue clearing reagents and kits that allow for the complete 3D characterization of tissues through the use of confocal and light sheet microscopy. However, over the last few years, Visikol has transitioned into an imaging, image analysis and advanced cell culture focused contract research organization and today offers 3D tissue imaging as a service as well as digital pathology and 3D cell culture assays.

"To support our 3D tissue imaging services and products, we had developed a large suite of image analysis tools for both 2D and 3D data sets and began to apply these tools to help our Clients with their traditional 2D slide-based samples in 2017. Beginning to offer digital pathology services a little over two years ago was the logical next step in offering best-in-class imaging and drug discovery services to our Clients," described Visikol Chief Executive Officer Dr. Michael Johnson.

Visikol offers pathology services to its Clients that include traditional H&E and IHC tissue preparation, slide scanning, fluorescent immunolabeling and multiplex labeling as well as imaging. All of these services can leverage either Visikol's 3Screen™ image analysis software suite and/or evaluation by a board-certified Pathologist. At CAP this year, Visikol will be specifically focusing its presentations and data on immuno-oncology digital pathology and multiplex imaging. Visikol has demonstrated the ability to acquire a tremendous amount of information from a single slide and to answer many complex questions such as quantifying immune cell infiltration kinetics as well as how different immune cell sub-types behave.

Due to the cost of immuno-oncology therapeutics and consequently patient/animal data and samples, it is crucial to extract as much information as is possible from a single piece of tissue in order to better inform a clinical trial or a drug discovery program. Visikol partners closely with its pharmaceutical Clients to understand their specific research questions in order to create a labeling and data analysis plan for every tissue. Once wet tissues, FFPE blocks or slides are transferred to Visikol, the team at Visikol leverages its validated antibodies and immunolabeling approaches to ensure the highest quality imaging data is obtained through either slide scanning or automated confocal microscopy. After Visikol has generated a library of imaging data or a Client has transferred their own imaging data to Visikol, the team works to create and validate a robust image analysis pipeline for distilling this data down into the Clients desired endpoints.

As a company in the digital pathology space, Visikol is very unique with its expertise in advanced image analysis and multiplex imaging, but also because it leads the field in clinical digital pathology solutions. While there are several companies pursuing applications of machine learning and digital pathology in the clinic to address pathology limitations, Visikol was actually one of the first to accomplish this task through its development of digital pathology machine learning software to support the development of Enzyvant Therapeutic’s RVT-802.

Therefore, if you are interested in discussing your digital pathology projects in more detail with the field's leading experts, stop by Visikol booth #216 or check out our services on our website.

About Visikol
Visikol is a CRO focused on advanced drug discovery that is leading the fields of bio-imaging, bioinformatics and image analysis. We conduct end-to-end drug discovery services that include both 2D and 3D in vitro models and assays, 3D whole mount tissue imaging, digital pathology and custom drug discovery projects. Visikol offers a portfolio of drug discovery services ranging from 2D and 3D cell culture model and assay development to in vitro screening, animal tissue histology and automated image processing. The focus of these services is to transform tissues into images and ultimately into quantitative data sets that can be mined for actionable insights that help our Clients make more informed decisions during the drug discovery process. Additionally, Visikol manufactures and sells a suite of tissue clearing reagents and 3D immuno-labeling kits. These products allow researchers to easily and rapidly image whole tissues and 3D cell culture models in 3D instead of traditional 2D sectioning. For more information about Visikol or its services, please visit our website at

Read the full story at

Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved

Related biology technology :

1. Visit Cole-Parmer at INTERPHEX 2013 and See Versatile Masterflex Technologies
2. J. Craig Venter Institutes Mobile Genomics Lab Launches First School Visits in San Diego County
3. Visiting Nurse Association of Northern New Jersey Announces Gardening Program at Friendship House Adult Day Care
4. Southwest Michigan Life Science Region Offers Virtual Visit Oct. 9
5. Omnia Education Expects Record Turnout for the 10th Annual Women's Health Annual Visit and Stages in Women's Health Capstone Medical Education Conference in New York City
6. Visit the New Tampa Chiropractor, Dr. Christine Rogers, at Elan Wellness Center of Tampa That's Providing Real Relief from All Types of Physically Related Pain
7. U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts
8. Emergency Department Visits For Heart Attacks Decline 24 Percent
9. William Pate, a Former Chief Marketing Officer of BellSouth and Current CEO of Atlanta Convention and Visitors Bureau, Joins PogoTec™ Board of Directors
10. Dr. Peter Schultz, CEO of The Scripps Research Institute, Visits WuXi AppTec Headquarters in Shanghai
11. Representative Scott Peters Visits Avelas Biosciences
Post Your Comments:
(Date:2/19/2020)... ... 2020 , ... Shoreline Biome, a microbiome research ... recently unveiled a novel DNA isolation product. , Shoreline Rapid Prep is a ... weight (HMW) single-stranded DNA (ssDNA) in excess of 40 kB from Gram-negative bacteria, ...
(Date:2/11/2020)... ... February 11, 2020 , ... ... the successful results from a long-term follow-up clinical study of outpatient L4-L5 ... device (INSPAN LLC). Unlike extension block design, the Inspan device fixates the ...
(Date:2/5/2020)... ... ... Rare Disease Day® , held the last day in February each ... to raise awareness amongst the general public and decision-makers about rare diseases and their ... rare disease series will be shining the light on Rare Disease Day ...
(Date:1/28/2020)... ... January 28, 2020 , ... Genedata, ... the release of Genedata Expressionist ® 13.5 at the 2020 WCBP ... Methods (MAM) for characterizing and monitoring the quality of biopharmaceuticals throughout their ...
Breaking Biology Technology:
(Date:1/29/2020)... , ... January 29, 2020 , ... ... the new Analytics and Data Sciences practice, providing consulting services for strategy, research ... was announced by Mike Townley, co-founder and Managing Partner of CREO, an innovative ...
(Date:1/28/2020)... OF PRUSSIA, Pa. and CAMBRIDGE, Mass. (PRWEB) , ... ... ... dedicated to solving complex problems for life sciences companies and government agencies, announced ... largest life sciences hubs in the country. Tunnell’s Cambridge office will be in ...
(Date:1/27/2020)... ... January 27, 2020 , ... Cytonus Therapeutics Inc. today announced ... entrepreneur, and former senior management consultant at McKinsey & Company who holds three ... investment firm. , “Chris Thorne has exceptional business acumen with a proven ...
Breaking Biology News(10 mins):